Dipòsit Digital de Documents de la UAB 4 registres trobats  La cerca s'ha fet en 0.03 segons. 
1.
23 p, 3.1 MB Short-Acting Beta-2-Agonist Exposure and Severe Asthma Exacerbations : SABINA Findings From Europe and North America / Quint, Jennifer K. (Imperial College London) ; Arnetorp, Sofie (Payer Analytics. AstraZeneca) ; Kocks, Janwillem W.H. (University Medical Center Groningen) ; Kupczyk, Maciej (Karolinska Institutet (Estocolm, Suècia)) ; Nuevo, Javier (Evidence Generation. AstraZeneca) ; Plaza, Vicente (Institut d'Investigació Biomèdica Sant Pau) ; Cabrera, Claudia (BioPharmaceuticals Medical (Evidence). AstraZeneca) ; Raherison-Semjen, Chantal (Bordeaux University) ; Walker, Brandie (University of Calgary) ; Penz, Erika (University of Saskatchewan) ; Gilbert, Ileen (Medical Affairs. AstraZeneca) ; Lugogo, Njira Lucia (University of Michigan) ; van der Valk, Ralf J.P. (Medical Affairs. AstraZeneca) ; Fong, Andrew ; Qian, Christina ; Fabry-Vendrand, Caroline ; Touboul, Chantal ; Brzostek, Dorota ; Maslova, Ekaterina ; Surmont, Filip ; Goike, Helena ; Gandhi, Hitesh ; Korevaar, J.C. ; Tkacz, Joseph ; Johnston, Karissa ; Peres da Costa, Keith ; van Dijk, L. ; Vervloet, M. ; Pollack, Michael ; Hernandez, Paul ; Boarino, S. ; Noorduyn, Stephen G. ; Beekman-Hendricks, Wendy ; Weesie, Y.M. ; Universitat Autònoma de Barcelona
Expert national/global asthma management recommendations raise the issue whether a safe threshold of short-acting beta-2 agonist (SABA) use without concomitant inhaled corticosteroids (ICS) exists. To examine SABA and maintenance therapy associations with severe asthma exacerbations across North America and Europe. [...]
2022 - 10.1016/j.jaip.2022.02.047
Journal of Allergy and Clinical Immunology: In Practice, Vol. 10 Núm. 9 (september 2022) , p. 2297-2309.e10  
2.
9 p, 397.0 KB Determinants and Differences in Satisfaction with the Inhaler Among Patients with Asthma or COPD / Plaza, Vicente (Institut d'Investigació Biomèdica Sant Pau) ; Giner, Jordi (Institut d'Investigació Biomèdica Sant Pau) ; Curto Sánchez, Elena (Institut d'Investigació Biomèdica Sant Pau) ; Alonso-Ortiz, M. Belén (Hospital Universitario de Gran Canaria Doctor Negrín Las Palmas de Gran Canaria) ; Orue, Miren Itxaso (Centro de Salud Javier Sáenz de Buruaga (Bilbao, País Basc)) ; Vega, José María (Hospital Regional Universitario de Málaga (Màlaga, Andalusia)) ; Cosio, Borja G. (Institut d'Investigació Sanitària Illes Balears (Mallorca, Balears)) ; Bellido Linares, Virginia (Hospital Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ; Mora, Roberto Bernabeu (Hospital General Universitario Morales Meseguer (Múrcia)) ; Cabrera César, Eva (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ; Callero Viera, Ariel (Hospital Universitario Ntra. Sra.de Candelaria (Santa Cruz de Tenerife)) ; Castillo, Rafael (Hospital de Llíria) ; Delgado Romero, Julio (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ; de los Monteros-Garde, Mª José Espinosa (Hospital Virgen de la Salud) ; Fernández Rodríguez-Lacín, José María (Centro de Salud Nata-hoyo) ; García Robaina, José Carlos (Hospital Universitario Nuestra Señora de Candelaria (Santa Cruz de Tenerife)) ; Hernández Gil, Aníbal Manuel (Hospital Comarcal de Laredo) ; Hernández Rey, José Miguel (Hospital Punta de Europa) ; Santana, Guacimara Hernández (Hospital Punta de Europa) ; López Ruiz, Cristina (Hospital Universitari Vall d'Hebron) ; Balaguer, Enrique Mascaros (Centro de Salud Fuente San Luis) ; Mazo Echaniz, Francisco Javier (Hospital de Basurto (Bilbao, Biscaia)) ; Moreno Pérez, Núria (Hospital Universitari Vall d'Hebron) ; Arrondo, Antoni Parra (Hospital Abente y Lago) ; Sánchez, José Portillo (Hospital General Universitario de Ciudad Real) ; Rodríguez Encinar, José Ramón (Centro de Salud Arroyo de la Media Legua) ; Rodríguez Plata, Elena (Hospital Universitario Nuestra Señora de Candelaria (Santa Cruz de Tenerife)) ; Román Bernal, Berta (Hospital Dr. José Molina Osora) ; Cunill Sala, Anna (Hospital Universitari Vall d'Hebron) ; Sánchez Lora, Fernando J. (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ; Sánchez Nieto, Juan Miguel (Hospital General Universitario Morales Meseguer (Múrcia)) ; Serra Batlles, Joan (Hospital Universitari de Vic) ; Torres Relucio, José Joaquín (Hospital General Universitari de Castelló (País Valencià)) ; Valido Morales, Agustín S. (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ; Vázquez Alarcón, Rubén Luciano (Centro de Salud VERA) ; Velasco Garrido, José Luis (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ; Universitat Autònoma de Barcelona
Satisfaction with the inhaler is an important determinant of treatment adherence in patients with asthma and chronic obstructive pulmonary disease (COPD). However, few studies have compared these 2 groups to identify the factors associated with satisfaction with the inhaler. [...]
2020 - 10.1016/j.jaip.2019.09.020
Journal of Allergy and Clinical Immunology: In Practice, Vol. 8 Núm. 2 (february 2020) , p. 645-653  
3.
9 p, 430.4 KB Dupilumab Efficacy in Steroid-Dependent Severe Asthma by Baseline Oral Corticosteroid Dose / Domingo, Christian (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Maspero, Jorge F (Fundación CIDEA) ; Castro, Mario (University of Kansas School of Medicine) ; Hanania, Nicola A. (Baylor College of Medicine) ; Ford, Linda B (Asthma & Allergy Center) ; Halpin, David M G (College of Medicine and Health) ; Jackson, David J (King's College London) ; Daizadeh, Nadia (Sanofi-Syntelabo) ; Djandji, Michel (Sanofi-Syntelabo) ; Mitchell, Colin P (Sanofi-Syntelabo) ; Crikelair, Nora (Regeneron Pharmaceuticals. Inc) ; Jacob-Nara, Juby A (Sanofi-Syntelabo) ; Deniz, Yamo (Regeneron Pharmaceuticals. Inc) ; Rowe, Paul J (Sanofi-Syntelabo) ; Ortiz, Benjamin (Regeneron Pharmaceuticals. Inc) ; Universitat Autònoma de Barcelona. Departament de Medicina
Background: Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4/-13, key and central drivers of type 2 inflammation in multiple diseases. In the phase 3 LIBERTY ASTHMA VENTURE (VENTURE) study (NCT02528214), dupilumab versus placebo reduced oral corticosteroid (OCS) dose and improved clinical outcomes in patients with OCS-dependent severe asthma. [...]
2022 - 10.1016/j.jaip.2022.03.020
The Journal of allergy and clinical immunology. In practice, Vol. 10 Núm. 7 (July 2022) , p. 1835-1843  
4.
9 p, 537.0 KB Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab : A Multicenter, Open-Label Pilot Study / Pérez de Llano, Luis (Hospital Universitario Lucus Augusti (Lugo)) ; Cosio, Borja G. (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ; Domingo, Christian (Universitat Autònoma de Barcelona. Departament de Medicina) ; Urrutia, Isabel (Hospital de Galdakao (Usansolo, Biscaia)) ; Bobolea, Irina (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Valero, Antonio (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Entrenas Costa, Luis M. (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ; Quirce Gancedo, Santiago (Hospital Universitario La Paz (Madrid)) ; Barranco, Pilar (Hospital Universitario La Paz (Madrid)) ; Marina Malanda, Nuria (Hospital Universitario de Cruces (Barakaldo, País Basc)) ; Prieto Andrés, Luis (Hospital Universitari Doctor Peset (València)) ; Alvarez-Gutiérrez, Francisco J. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
Background: Patients with severe allergic and eosinophilic asthma could qualify for different biologic therapies. Objective: To evaluate the efficacy and safety of weight-based intravenous reslizumab dosing in patients who have previously failed therapy with omalizumab. [...]
2019 - 10.1016/j.jaip.2019.01.017
The Journal of allergy and clinical immunology. In practice, Vol. 7 Núm. 7 (september 2019) , p. 2277-2283.e2  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.